We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lifts Partial Clinical Hold on Trials for OncoMed’s Vantictumab
FDA Lifts Partial Clinical Hold on Trials for OncoMed’s Vantictumab
Cancer drugmaker OncoMed expects to resume enrollment and dosing of new patients for its experimental oncology drug vantictumab within the next few weeks, after the FDA removed a partial clinical hold on its clinical trials.